Research Article
Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion
Table 2
Clinical characteristics of 4 patients who developed subclinical cardiotoxicity.
| | Age (years) | Mean cumulative dose (mg/m2) | Number of chemotherapy cycles | Baseline LVEF (%) | Baseline troponin I levels (ng/ml) | Midstudy troponin I levels (ng/ml) | End-study troponin I (ng/ml) | Baseline BNP (ng/dl) | Midstudy BNP (ng/dl) | End-study BNP (ng/dl) | Tumor response |
| | 45 | 405 | 6 | 65 | <0.05 | <0.05 | <0.05 | 4.9 | 4.9 | 11.7 | Neoadjuvant | | 44 | 360 | 4 | 77 | <0.05 | <0.05 | NA | 6.6 | 4.9 | NA | Neoadjuvant | | 32 | 525 | 6 | 66 | <0.05 | <0.05 | <0.05 | 4.9 | 4.9 | 4.9 | Stable disease | | 53 | 450 | 5 | 68 | <0.05 | <0.05 | <0.05 | 4.9 | 4.9 | 4.9 | Stable disease |
|
|
